Literature DB >> 35359181

Evaluation of the apolipoprotein E (apoE)-HDL-associated risk factors for coronary heart disease using duo-functional electrochemical aptasensor.

Ching-Ying Tsai1, Deng-Ying Huang2, Ja-An Annie Ho3,4,5,6, Li-Chen Wu7.   

Abstract

Apolipoprotein E containing high-density lipoprotein (apoE-HDL) and apoE-HDL cholesterol (apoE-HDL-C) are recently recognized as potential biomarkers for coronary heart disease (CHD). We herein developed a two-stage, enzyme-assisted, dual-signal aptasensor that enables a useful electrochemical sensing platform for simultaneous determination of apoE-HDL, apoE-HDL-C, and total HDL-C presented in the sample. The detection scheme consists of two subsystems. In subsystem (I), the level of apoE-HDL is evaluated upon the binding of apoE-specific aptamer and subsequently methylene blue (MB)-labeled DNA displacement occurs on the electrode surface, resulting in electrochemical reduction of methylene blue. In subsystem (II), two kinds of cholesterol levels (apoE-HDL-C and total HDL-C) can be measured. For apoE-HDL-C, the amount of cholesterol in apoE-HDL captured by the aptamer in the first step can be further determined with the aid of surfactant, cholesterol esterase, cholesterol oxidase, and p-aminophenol-mediated electrochemical signal amplification. As for total HDL-C, the amount of cholesterol is determined by the same approach as that used for apoE-HDL-C determination, but without washing (separation). The linear dynamic range for apoE-HDL determination is from 1 to 100 mg/dL (R2 = 1.00). For cholesterol standards, the linear dynamic range is determined to be 0-250 mg/dL (R2 = 0.98). Finally, serial dilutions of purified human HDL preparations were examined using the newly developed aptasensor; the percentage of apoE-HDL-C to HDL-C was found to be ~10%, which correlated well with previously reported values. In conclusion, we successfully developed an electrochemical aptasensor that allows concurrent quantification of apoE-HDL, apoE-HDL-C, and HDL-C on the same platform, offering an efficient, convenient, and purification-free sensing strategy for predictive CHD biomarkers.
© 2022. Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Aptasensor; CHD; Dual detection; Electrochemistry; apoE-HDL; apoE-HDL-C

Mesh:

Substances:

Year:  2022        PMID: 35359181     DOI: 10.1007/s00216-022-04008-4

Source DB:  PubMed          Journal:  Anal Bioanal Chem        ISSN: 1618-2642            Impact factor:   4.142


  21 in total

1.  HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events.

Authors:  Robert S Rosenson; H Bryan Brewer; M John Chapman; Sergio Fazio; M Mahmood Hussain; Anatol Kontush; Ronald M Krauss; James D Otvos; Alan T Remaley; Ernst J Schaefer
Journal:  Clin Chem       Date:  2011-01-25       Impact factor: 8.327

Review 2.  Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization.

Authors:  S Yusuf; S Reddy; S Ounpuu; S Anand
Journal:  Circulation       Date:  2001-11-27       Impact factor: 29.690

3.  A rapid and simple quantification of human apolipoprotein E-rich high-density lipoproteins in serum.

Authors:  H Chiba; K Akizawa; S Fujisawa; T Osaka-Nakamori; N Iwasaki; H Suzuki; S Intoh; K Matsuno; T Mitamura; K Kobayashi
Journal:  Biochem Med Metab Biol       Date:  1992-02

4.  Effect of torcetrapib on the progression of coronary atherosclerosis.

Authors:  Steven E Nissen; Jean-Claude Tardif; Stephen J Nicholls; James H Revkin; Charles L Shear; William T Duggan; Witold Ruzyllo; William B Bachinsky; Gabriel P Lasala; Gregory P Lasala; E Murat Tuzcu
Journal:  N Engl J Med       Date:  2007-03-26       Impact factor: 91.245

5.  A rapid and precise method for measuring plasma apoE-rich HDL using polyethylene glycol and cation-exchange chromatography: a pilot study on the clinical significance of apoE-rich HDL measurements.

Authors:  Toru Ikeda; Ryoko Shinohata; Masaaki Murakami; Kazuyoshi Hina; Shigeshi Kamikawa; Satoshi Hirohata; Shozo Kusachi; Arisa Tamura; Shinichi Usui
Journal:  Clin Chim Acta       Date:  2016-12-18       Impact factor: 3.786

6.  HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway.

Authors:  Fumihiko Matsuura; Nan Wang; Wengen Chen; Xian-Cheng Jiang; Alan R Tall
Journal:  J Clin Invest       Date:  2006-05       Impact factor: 14.808

7.  High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study.

Authors:  T Gordon; W P Castelli; M C Hjortland; W B Kannel; T R Dawber
Journal:  Am J Med       Date:  1977-05       Impact factor: 4.965

8.  Apolipoprotein E4 forms a molten globule. A potential basis for its association with disease.

Authors:  Julie A Morrow; Danny M Hatters; Bin Lu; Peter Hochtl; Keith A Oberg; Bernhard Rupp; Karl H Weisgraber
Journal:  J Biol Chem       Date:  2002-10-21       Impact factor: 5.157

9.  Alterations in the concentration of an apolipoprotein E-containing subfraction of plasma high density lipoprotein in coronary heart disease.

Authors:  H M Wilson; J C Patel; D Russell; E R Skinner
Journal:  Clin Chim Acta       Date:  1993-11-15       Impact factor: 3.786

10.  Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies.

Authors:  Christian M Madsen; Anette Varbo; Børge G Nordestgaard
Journal:  Eur Heart J       Date:  2017-08-21       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.